CD147-CART

News alerts, weekly reports and conference planners

Company:

Air Force Medical University

Drug class:

CD147-targeted CAR-T immunotherapy

Related drugs:

‹

CD147-CAR T cells (0)

›

over3years

CD147-specific chimeric antigen receptor T cells effectively inhibit T cell acute lymphoblastic leukemia. (PubMed, Cancer Lett)

NOD/ShiLtJGpt-Prkdcem26Cd52Il2rgem26Cd22/Gpt mice were used to establish a T-ALL xenograft model and CD147-CAR T cells conferred robust protection against T-ALL progression and significantly improved survival in mice. Overall, we found that CD147 is a potential antigen target of CAR T cell therapy for T-ALL.

over 3 years ago

Journal • CAR T-Cell Therapy

CCR7 (Chemokine (C-C motif) receptor 7) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • BSG (Basigin (Ok Blood Group))

CD147-CART

4years

Chimeric antigen receptor T cells targeting CD147 for non-small cell lung cancer therapy. (PubMed, Transl Oncol)

Importantly, CD147-CART cells have strong anti-tumor activity against NSCLC cells in vivo in both CDX and PDX models and no adverse side effects. Our findings show that CD147-CART immunotherapy for NSCLC is safe and effective, which is an ideal and promising medical patch for treating NSCLC.

4 years ago

Journal • CAR T-Cell Therapy • IO biomarker

BSG (Basigin (Ok Blood Group))

CD147-CART